Veterinary Medicine Information website

Vanguard CPV-Lepto

Authorised
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Download as PDF

Product identification

Medicine name:
Vanguard CPV-Lepto
Active substance:
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    915.00
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
    740.00
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    7.00
    log10 50% cell culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI05
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Available in:
  • Netherlands
Package description:
  • Blister met 25 glazen (Type I) injectieflacons met rubberstop en metalen felscapsule à 1 dosis vaccin.
  • Blister met 100 glazen (Type I) injectieflacons met rubberstop en metalen felscapsule à 1 dosis vaccin.
  • Blister met 10 glazen (Type I) injectieflacons met rubberstop en metalen felscapsule à 1 dosis vaccin.
  • Blister met 1 glazen (Type I) injectieflacon met rubberstop en metalen felscapsule à 1 dosis vaccin.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Zoetis B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 8371
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 29/03/2023
Download